

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

RT-112

RRID:CVCL_1670

Type: Cell Line

Proper Citation

RRID:CVCL_1670

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1670

Proper Citation: RRID:CVCL_1670

Description: Cell line RT-112 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Bladder carcinoma

Defining Citation: [PMID:571047](#), [PMID:864752](#), [PMID:870558](#), [PMID:2144165](#), [PMID:2903891](#), [PMID:3708594](#), [PMID:6823318](#), [PMID:7490993](#), [PMID:8873383](#), [PMID:11207054](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12127398](#), [PMID:15846775](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:26589293](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28855393](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RT-112

Synonyms: RT 112, RT112

Cross References: BTO:BTO_0003724, CLO:CLO_0008890, EFO:EFO_0006479, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:383, BioSample:SAMN03473091, BioSample:SAMN03473589, BioSample:SAMN10988358, cancercellines:CVCL_1670, Cell_Model_Passport:SIDM00402, ChEMBL-Cells:ChEMBL3307307, ChEMBL-Targets:ChEMBL614145, CLS:300324, Cosmic:715739, Cosmic:760482, Cosmic:845559, Cosmic:867837, Cosmic:909704, Cosmic:925820, Cosmic:928823, Cosmic:1046682, Cosmic:1068092, Cosmic:1285124, Cosmic:1285984, Cosmic:1819324, Cosmic:1938478, Cosmic:1938697, Cosmic:2037954, Cosmic:2050459, Cosmic:2057454, Cosmic:2444244, Cosmic:2686111, Cosmic-CLP:909704, DepMap:ACH-000473, DSMZ:ACC-418, DSMZCellDive:ACC-418, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909704, GEO:GSM887552, GEO:GSM888635, GEO:GSM1374857, GEO:GSM1374858, GEO:GSM1574545, GEO:GSM1574581, GEO:GSM1670393, IARC_TP53:13322, LiGeA:CCLE_846, LINCS_LDP:LCL-1716, PharmacDB:RT112_1332_2019, PRIDE:PXD030304, Progenetix:CVCL_1670, PubChem_Cell_line:CVCL_1670, Wikidata:Q54951347

ID: CVCL_1670

Record Creation Time: 20220427T221508+0000

Record Last Update: 20260920T005623+0000

Ratings and Alerts

No rating or validation information has been found for RT-112.

No alerts have been found for RT-112.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer cell, 44(5), 995.

Schmitz J, et al. (2026) Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. Molecular oncology, 20(3), 779.

Kabus M, et al. (2026) Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells. Scientific reports, 16(1).

Takemoto K, et al. (2025) DGK? Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. Cancer medicine, 14(5), e70710.

Pannhausen J, et al. (2025) Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. *Scientific reports*, 15(1), 13443.

Yu Y, et al. (2025) A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. *Cancer research*, 85(12), 2288.

Tasaka R, et al. (2025) KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy resistance in bladder cancer by suppressing ROS accumulation. *Urologic oncology*.

Satpathy S, et al. (2025) Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. *Cancer cell*, 43(9), 1731.

Lee S, et al. (2024) Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. *Cell reports*, 43(5), 114146.

Ranti D, et al. (2024) HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. *bioRxiv : the preprint server for biology*.

Dressler FF, et al. (2024) Proteomic analysis of the urothelial cancer landscape. *Nature communications*, 15(1), 4513.

Tortora D, et al. (2023) A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. *iScience*, 26(5), 106525.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Klümper N, et al. (2023) PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. *Oncoimmunology*, 12(1), 2267744.

Chen L, et al. (2023) PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. *Cell & bioscience*, 13(1), 45.

Rehman H, et al. (2022) ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. *JCI insight*, 7(16).

An M, et al. (2022) Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer. *Cancer research*, 82(12), 2239.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. *Cancer cell*, 40(9), 1027.

Greenstein AE, et al. (2021) Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. *Oncotarget*, 12(13), 1243.

Crump NT, et al. (2021) Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. *Cell reports*, 35(6), 109101.